[1] Kwatra S G, Batson N E, Kramer S I. Long-acting risperidone and oral antipsychotics in schizophrenia[J]. N Engl J Med, 2011,364(23):2264-2265, 265-266.[2] Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials[J]. BMJ, 2010,341:c4737.[3] 苏金哥,郭红丽,王秀芳,等.精神药物的不良反应[J].临床精神医学杂志,2012,1:69-70.[4] 孙成文,王汉斌,等.精神药物中毒的快速定性检测[J].中华精神科杂志,2001,34(4):239.[5] 张梦琪,贾晶莹,陆晓佩,等.LC-MS/MS同时测定人血清中5种抗精神类药物和9种抗抑郁药物的浓度[J].中国药学杂志,2011,46(1):51-60.[6] Rao L V, Snyder M L, Vallaro G M. Rapid liquid chromatography/tandem mass spectrometer(LCMS) method for clozapine and its metabolite N-desmethyl clozapine(norclozapine) in human serum[J]. J Clin Lab Anal, 2009,23(6):394-398.[7] Locatelli I, Mrhar A, Grabnar I. Simultaneous determination of risperidone and 9-hydroxyrisperidone enantiomers in human blood plasma by liquid chromatography with electrochemical detection[J]. J Pharm Biomed Anal, 2009,50(5):905-910.[8] 尹明兰.HPLC法同时监测5种抗精神病药血药浓度[J].中国药房,2007,18(11):837-838.[9] Ragg M A, Mandrioli R, Casamenti G, et al. Determination of reboxetine, a recent antidepressant drug, in human plasma by means of two high-performance liquid chromatography methods[J]. J Chromatogr A, 2002,949(1-2):23-33.[10] 国家药典委员会.中华人民共和国药典(二部)[M].北京:中国医药科技出版社,2010.[11] 张剑萍,郭澄.生物样品分析中的方法学验证[J].中国药房,2008(31):2469-2471.[12] Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011[J]. Pharmacopsychiatry, 2011,44(6):195-235.[13] 周小东,付华斌,刘知源,等.新型抗精神病药物研发过程中面临的问题和解决方案[J].解放军医药杂志,2012,24(2):33-37.[14] 郑晓人,高镇松,刘南华,等.抗精神病药物中毒患者的精神心理和个性研究[J].中国煤炭工业医学杂志,2010,13(5):669-671. |